

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 May 2019 (09.05.2019)



(10) International Publication Number
WO 2019/089650 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) C12N 5/0783 (2010.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)
C07K 14/725 (2006.01)

(21) International Application Number:

PCT/US2018/058288

(22) International Filing Date:

30 October 2018 (30.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/579,426	31 October 2017 (31.10.2017)	US
62/716,898	09 August 2018 (09.08.2018)	US
62/750,215	24 October 2018 (24.10.2018)	US

(71) Applicants: **ALLOGENE THERAPEUTICS, INC.**
[US/US]; 270 Littlefield Avenue, South San Francisco, California 94080 (US). **LES LABORATOIRES SERVIER**
[FR/FR]; 35, rue de Verdun, 92284 Suresnes Cedex (FR).

(72) Inventors: **KONTO, Cyril Alkis**; c/o Allogene Therapeutics, Inc., 270 Littlefield Avenue, South San Francisco, California 94080 (US).

ifornia 94080 (US). **ZINAI, Amina**; c/o Les Laboratoires Servier, 35, rue de Verdun, 92284 Suresnes Cedex (FR).


(74) Agent: **FOLEY, Erin M.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS

FIG. 4A



(57) Abstract: The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*